Cucurbitacin E as a new inhibitor of cofilin phosphorylation in human leukemia U937 cells

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 9, 2010, Pages 2994-2997

  Nakashima, Souichi ^a   Matsuda, Hisashi ^a   Kurume, Ai ^a   Oda, Yoshimi ^a   Nakamura, Seikou ^a   Yamashita, Masayuki ^a   Yoshikawa, Masayuki ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Biotin linked cucurbitacin E; Cofilin; Cucurbitacin E; Cucurbitane type triterpene; Cytotoxic effect; Target protein

Indexed keywords

COFILIN; CUCURBITACIN; CUCURBITACIN E; CUCURBITACIN I; F ACTIN; G ACTIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CELL STRAIN U937; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DEPOLYMERIZATION; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LEUKEMIA CELL; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING;

ACTINS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COFILIN 1; HUMANS; PHOSPHORYLATION; STAT3 TRANSCRIPTION FACTOR; TRITERPENES; U937 CELLS;

EID: 77950864226     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.02.062     Document Type: Article

References (31)

1. Kaufmann S.H. Cancer Res. 49 (1989) 5870
2. Friesen C., Herr I., Krammer P.H., and Debatin K.M. Nat. Med. 2 (1996) 574
3. Fulda S., and Debatin K.M. Curr. Med. Chem. Anticancer Agents 3 (2003) 253
4. Sedletska Y., Giraud-Panis M.J., and Malinge J.M. Curr. Med. Chem. Anticancer Agents 5 (2005) 251 and references cited therein
5. Bartalis J., and Halaweish F.T. J. Chromatogr. B 818 (2005) 159
6. Meng D., Qiang S., Lou L., and Zhao W. Planta Med. 74 (2008) 1741
7. Chen C., Qiang S., Luo L., and Zhao W. J. Nat. Prod. 72 (2009) 824
8. Blaskovich M.A., Sun J., Cantor A., Turkson J., Jove R., and Sebti S.M. Cancer Res. 63 (2003) 1270
9. Sun J., Blaskovich M.A., Jove R., Livingston S.K., Coppola D., and Sebti S.M. Oncogene 24 (2005) 3236
10. Shi X., Franko B., Franz C., Amin H.M., and Lai R. Br. J. Haematol. 135 (2006) 26
11. Matsuda, H.; Nakashima, S.; Abdel-Halim, O. B.; Morikawa, T.; Yoshikawa, M. Chem. Pharm. Bull. 2010, in press (c091036).
12. 2O (50:50, v/v)] to give 1 (31 mg, 80%).
13. Yoshikawa M., Morikawa T., Kobayashi H., Nakamura A., Matsuhira K., Nakamura S., and Matsuda H. Chem. Pharm. Bull. 55 (2007) 428
14. 15 (7 mg, 38%).
15. Velde V.V., and Lavie D. Tetrahedron 39 (1983) 317
16. 50 value was determined graphically.
17. 50 values of cucurbitacins B and D and 23,24-dihydrocucubitacins B and E were 13 nM, 0.28 μM, 0.29 μM, and 3.1 μM in HL60 cells and 27 nM, 0.50 μM, 1.2 μM, and 9.6 μM in HT1080 cells, respectively. These results confirm the importance of a double bond at the 23,24-positions as well as an acetoxy group at the 25-position.
18. Amin H.M., McDonnell T.J., Ma Y., Lin Q., Fujio Y., Kunisada K., Leventaki V., Das P., Rassidakis G.Z., Cutler C., Medeiros L.J., and Lai R. Oncogene 23 (2004) 5426
19. Turkson J., Zhang S., Mora L.B., Burns A., Sebti S., and Jove R. J. Biol. Chem. 280 (2005) 32979
20. Lin Q., Lai R., Chirieac L.R., Li C., Thomazy V.A., Grammatikakis I., Rassidakis G.Z., Zhang W., Fujio Y., Kunisada K., Hamilton S.R., and Amin H.M. Am. J. Pathol. 167 (2005) 969
21. Yang L., Wu S., Zhang Q., Liu F., and Wu P. Cancer Lett. 256 (2007) 267
22. 2/M phase were analyzed using cell cycle analysis software, ModFit LT ver. 3.0 (Verity Software House).
23. 4 cells/mL) were incubated with the test compounds for 24 h. They were then lysed in a lysis buffer containing a phosphatase inhibitor (Roche) and a proteinase inhibitor (Thermo Scientific). Protein concentrations of cell lysate were determined using the Protein Assay Kit (Thermo Scientific). Equivalent amounts of protein (60 μg or 30 μg of protein/lane) were electrophoresed in 10% SDS-polyacrylamide gels and transferred to polyvinylidene difluoride membranes. The membranes were blocked for 30 min in Blocking One or Blocking One-P (Nacalai Tesque). The blots were probed with primary antibody at the appropriate dilution in Tris-buffered saline containing 0.1% Tween 20 (T-TBS) for 1 h. The membranes were then washed three times with T-TBS and incubated with the appropriate HRP-conjugated secondary antibody for 1 h. Immunoreactive proteins were detected using an enhanced chemiluminescence kit (ECL plus, GE Healthcare), according to the manufacturer's instructions. The following antibodies and dilutions were used for Western blotting: rabbit polyclonal antibody against anti-phospho-STAT3, anti-STAT3, anti-phospho-cofilin, anti-phospho-LIMK1/2, anti-β-actin (1:1000) (Cell Signaling Technology); anti-rabbit IgG; and HRP-linked whole antibody from donkeys (1:5000) (GE Healthcare).
24. +.
25. Yamazaki K., Kohno K., Yasui H., Kiso Y., Akamatsu M., Nicholson B., Deyanat-Yadzi G., Neuteboom S., Potts B., Lloyad G.K., and Hayashi Y. ChemBioChem 9 (2008) 3074
26. Details regarding in-gel digestion, LC-MS/MS analysis, and the Scaffold algorithm can be found in the technical information section of the website of NextGen Sciences (www.nextgensciences.com).
27. Carlier M.F., Ressad F., and Pantaloni D. J. Biol. Chem. 274 (1999) 33827
28. Condeelis J. Trends Cell Biol. 11 (2001) 288
29. Arber S., Barbayannis F.A., Hanser H., Schneider C., Stanyon C.A., Bernard O., and Caroni P. Nature 393 (1998) 805
30. Yang N., Higuchi O., Ohashi K., Nagata K., Wada A., Kangawa K., Nishida E., and Mizuno K. Nature 393 (1998) 809
31. Toshima J., Toshima J.Y., Takeuchi K., Mori R., and Mizuno K. J. Biol. Chem. 276 (2001) 31449